Pediatric visceral leishmaniasis in Albania  by Lito, Gjeorgjina et al.
Original Report 
Pediatric visceral leishmaniasis in Albania 
Gjeorgjina Lito,(l) Farzin Davachi,c2) Gent Sulcebe,(3) Hamide Breg&) and Mira Basha 
Objective: Visceral leishmaniasis (VL) in children is endemic in southern Europe but has not been previously 
reported from Albania. This prospective study reports the clinical and laboratory findings in 50 children with 
visceral leishmaniasis, the value of a direct agglutination test (DAT), and the result of treatment with meglumine 
antimonate. 
Materials and Methods: Sera obtained from 50 children with VL confirmed by bone marrow examination, 40 house- 
hold contacts, and 30 hospitalized children with other infections were examined using DAT. 
Results: Clinical features included fever (lOO%), hepatosplenomegaly (lOO%), pallor (lOO%), weight loss 
(98%), vomiting (68%), diarrhea (32%), and bleeding disorders (8%). Laboratory findings were anemia (94%), 
neutropenia (85%), hypergammaglobulinemia (70%), and thrombocytopenia (22%). Thirty children who developed 
secondary bacterial infections had significantly lower hemoglobin and neutrophil counts (P<O.OOOl). Direct 
agglutination test had a sensitivity of 98%) a specificity of 100%) and a positive predictive value of 100%. One child 
with severe generalized bleeding died within 48 hours of admission before receiving treatment. 
Conclusion: The direct agglutination test was highly valuable in diagnosis of VL in this series. Meglumine anti- 
monate was an effective therapeutic agent. Post-treatment bone marrow examination confirmed recovery in all 
patients. There were no relapses of VL during one-year follow up. 
Int J Infect Dis 2002; 6: 66-68 
Visceral leishmaniasis (VL) in children is reported from 
many regions of the world,l-1° Although it is endemic in 
Albania, it has not been previously reported. Therefore, 
a prospective study was designed at the University 
Hospital Center of Tirana to describe the clinical 
features of VL in children and to evaluate the diag- 
nostic accuracy of the direct agglutination test (DAT) 
and the results of treatment with meglumine anti- 
monate (Glucantime, Rh8ne Poulenc, Paris). 
PATIENTS AND METHODS 
The study group consisted of 50 children with visceral 
leishmaniasis confirmed by the presence of amastigotes 
in Giemsa-stained bone marrow aspirate. Forty healthy 
household contacts and 30 pediatric patients served as 
controls. Parental consent was obtained for each child. 
The sera obtained from the patients with VL and the 
control groups were examined by DAT. A leishmania 
antibody titer greater than 1:3200 was considered 
positive. 
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All patients with VL were treated with daily 
intramuscular injections of meglumine antimonate 
(60-80 mg/kg/24 h, equivalent to 20 mg Sb5+/kg/24 h) 
for 21 consecutive days. A bone marrow examination 
was done at the end of treatment. Patients with a 
positive bone marrow examination after the first cycle 
of treatment received meglumine antimonate for an 
additional 10 days after a 2-week interval. Children 
with severe anemia or pancytopenia were given blood 
transfusions. Children with secondary bacterial infec- 
tions received antibiotic therapy. Patients were reexam- 
ined at 1,6, and 12 months following discharge. 
RESULTS 
Thirty boys and 20 girls with VL, ranging in age from 4 
months to 12 years (mean, 2.55 y) were admitted to the 
Section of Pediatric Infectious Diseases at the Univer- 
sity Hospital Center of Tirana. Two infants (4%) were 4 
to 6 months, 13 (26%) were 7 to 12 months, 11 (22%) 
were 13 to 18 months, 10 children (20%) were 2 to 5 
years, and 3 (6%) were more than 5 years old. 
Patients were referred from all parts of the country, 
especially from the north, where the infection is more 
prevalent. Duration of symptoms before admission 
ranged from 2 weeks to 8 weeks. Children presented 
with pallor (lOO%), hepatosplenomegaly (lOO%), and 
hyperthermia (100%). Thirty-five (70%) had a fever of 
more than 39°C associated with perspiration and chills. 
There was considerable splenomegaly, ranging from 4 
to 12 cm. Twenty-four children (48%) had a palpable 
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spleen larger than 7 cm. Weight loss was observed in 49 
patients (98%), vomiting in 34 (68%), diarrhea in 16 
(32%), and bleeding disorders and lymphadenopathy in 
4 (8%) patients. 
Laboratory examination revealed 47 (94%) children 
with a hemoglobin level of less than 10 g/dL, 24 (48%) 
with a hemoglobin level of less than 7 g/dL, 45 (90%) 
with erythrocyte sedimentation rate higher than 30 
mm/h, 44 (85%) with neutropenia ( <1500/mm3), 37 
(74%) with leukopenia (<4000/mm3), 35 (70%) with 
gammaglobulinemia (>2 g/dL), 11 (22%) with a 
platelet count less than 100,000/mm3, and 1X (22%) 
with serum transaminase levels higher than 50 IU/L. 
Thirty children (60%) developed associated 
bacterial infections: 20 with pneumonia, four with pneu- 
monia and enteritis, three with pneumonia and otitis, 
one with gastroenteritis, one with otitis media, and 
one with soft-tissue abscess. The most commonly iso- 
lated microorganisms were Haemophilus injluenzae, 
Staphylococcus aureus, Streptococcus pneumoniae, 
Pseudomonas aeruginosa, Salmonella enteritidis and 
Salmonella typhimurium. There was no significant 
difference in the mean age of children with or without 
secondary bacterial infections: however, children who 
developed complications had significantly lower levels 
of hemoglobin and neutrophils (Table 1). 
A 15-month-old boy with generalized bleeding pre- 
sented with a 5-fold increase in alanine and aspartate 
aminotransferase values, prolonged prothrombin time 
(40 s), serum protein of 4 g/dL, and hypoproteinemic 
edema. Serologic studies for viral hepatitis A, B, and C 
were negative. The patient died 2 days after admission 
before receiving treatment. 
Direct agglutination test examinations revealed an 
antibody titer higher than 1:3200 in 49 (98%) patients. 
Forty (80%) patients had a DAT-titer higher than 
l:lOO,OOO. In all individuals in the control group, DAT 
was nonreactive (< 1:800). A 4-month-old baby was the 
only patient with a nonreactive serology. In this study, 
DAT had a sensitivity of 98%, specificity of lOO%, 
positive predictive value of 100%) and negative predic- 
tive value of 98 % . 
Meglumine antimonate (Glucantime; Rh8ne 
Poulenc, Paris) was well tolerated with no adverse 
effects. Forty (80%) patients responded to 21 days of 
treatment, whereas the remaining nine (18%) patients 
required an additional 10 day-course of treatment after 
Table 1. Mean age and hematological parameters in patients 
with and without secondary bacterial infections 
Parameters 
With Without 
bacterial bacterial 
infections infections P-values 
Mean age (mo) 25 34 >0.21 
Hemoglobin (g/dL) 6.76 8.1 <0.0001 
WBC/mm3 4300 6500 <0.0001 
Neutrophils/mm3 1300 2058 <0.0001 
a two-week interval. Clinical response, confirmed by the 
remission of fever, appeared approximately 5 to 8 days 
after the onset of treatment. Improvement in hemato- 
logic parameters appeared in the second and third week 
of treatment. Bone marrow studies at the end of treat- 
ment confirmed recovery in all children. None of the 
patients had a relapse during the one-year follow-up 
period. 
DISCUSSION 
Leishmaniasis denotes a group of varied syn- 
dromes caused by a number of species of the protozoa 
Leishmania. There is an overall prevalence of 12 million 
cases of leishmaniasis worldwide.ll The global incidence 
of visceral leishmaniasis is 500,000 new cases per year. 
Children acquire VL either by living in endemic areas 
or by travelling to those regions.12J3 In Albania, 
children comprise 70% of patients with VL. The 
incidence of VL in the patients in the present study was 
highest in the first 2 years of life, similar to that 
reported from North Africa and Pakistan.1,6T9 Other 
southern European countries, however, have reported a 
wider age range. l1 Patients with human immuno- 
deficiency virus or acquired immunodeficiency syn- 
drome (HIV/AIDS) are at greater risk of acquiring 
leishmaniasis.1°J4 A study from Alps Maritime in 
France, reported that 40% of adults with VL were HIV 
seropositive and that children represented only 28% of 
all patients.5 Although HIV serology was not done in 
these children, the higher incidence of VL in infants 
and children appears to be attributable to the preva- 
lence of malnutrition and a smaller number of adults 
with HIV/AIDS in Albania. 
Anemia is common in children with VL.15J6 
Consumption of iron bound to lactoferrin, transferrin, 
or hemin by the promastigotes may be one of the con- 
tributing factors.17 
Secondary bacterial infections were found in 30 
(60%) patients. Respiratory and gastrointestinal tract 
infections were the most common. These infections 
are associated with the depression of cell-mediated 
immunity to leishmania antigen and the presence of 
serum suppressor factors capable of suppressing the 
immune response.lsJ9 In the present study, patients with 
bacterial infections manifested significantly lower white 
blood cell count (WBC) and neutrophils (P<O.OOOl). In 
addition, these children were often malnourished, and 
they presented with anemia. The only child with fatal 
outcome in this study presented with hepatic compli- 
cation and generalized bleeding. 
The direct agglutination test is highly valuable.21-23 
In the present study, it had a sensitivity of 98%, speci- 
ficity of lOO%, and positive predictive value of lOO%, 
whereas positive bone marrow aspirate confirms the 
diagnosis of VL in 72 to 93 % of patients.5,8 The absence 
of antibody response in the 4-month-old infant could 
have been attributable to his young age. The culture of 
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bone marrow aspirate from patients with leishmaniasis 
in Albania isolated taxonomic complex of Leishmania 
infanturn, zymodeme MON=l. The children were 
examined at 1,6, and 12 months following discharge. 
There were no relapses. 
CONCLUSIONS 
Visceral leishmaniasis (L. infanturn, zymodeme MON 
=l) is endemic in Albania and is found predominantly 
in infants and children. Fever, hepatosplenomegaly, 
pallor, and anemia are common findings. Lower hemo- 
globin and WBC values were associated with the acqui- 
sition of bacterial infections. In this study, DAT had a 
sensitivity of 98%, specificity of lOO%, and positive 
predictive value of 100%. All children were treated 
with meglumine antimonate and responded well. They 
were followed for one year with no relapses of VL. 
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